NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee has approved inducement share options for four non-executive new hires. The grants cover 138,000 ordinary shares under the company's 2024 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4).
The share options were granted at an exercise price of $21.36, matching the closing market price of NAMS ordinary shares on February 3, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting in 36 equal monthly installments, contingent on continued employment.
NewAmsterdam Pharma (Nasdaq: NAMS) ha annunciato che il suo Comitato per la Remunerazione ha approvato opzioni di azioni induttive per quattro nuovi assunti non esecutivi. Le concessioni riguardano 138.000 azioni ordinarie nell'ambito del Piano di Induzione 2024 dell'azienda, conforme alla Regola di Quotazione 5635(c)(4) di Nasdaq.
Le opzioni azionarie sono state concesse a un prezzo di esercizio di $21,36, corrispondente al prezzo di chiusura delle azioni ordinarie di NAMS del 3 febbraio 2025. Il programma di vesting si estende per quattro anni, con il 25% che matura dopo un anno e le azioni rimanenti che maturano in 36 rate mensili uguali, contingentato su un impiego continuato.
NewAmsterdam Pharma (Nasdaq: NAMS) anunció que su Comité de Compensación ha aprobado opciones de acciones de inducción para cuatro nuevas contrataciones no ejecutivas. Las concesiones cubren 138,000 acciones ordinarias bajo el Plan de Inducción 2024 de la compañía, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones de acciones se otorgaron a un precio de ejercicio de $21.36, coincidiendo con el precio de cierre del mercado de las acciones ordinarias de NAMS el 3 de febrero de 2025. El calendario de adquisición se extiende por cuatro años, con un 25% de adquisición después de un año y las acciones restantes adquiriéndose en 36 cuotas mensuales iguales, dependiendo de la continuidad del empleo.
뉴암스테르담 제약 (Nasdaq: NAMS)는 보상 위원회가 네 명의 비임원 신입 직원을 위한 유도 주식 옵션을 승인했다고 발표했습니다. 이 부여는 회사의 2024 유도 계획에 따라 138,000주에 해당하며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
주식 옵션은 $21.36의 행사 가격으로 부여되었으며, 이는 2025년 2월 3일 NAMS 보통 주식의 시장 마감 가격에 해당합니다. 권리 부여 일정은 4년에 걸쳐 있으며, 1년 후 25%가 부여되고 나머지 주식은 계속 고용 조건에 따라 36개월 동안 동일한 월 할부로 부여됩니다.
NewAmsterdam Pharma (Nasdaq: NAMS) a annoncé que son Comité de Rémunération a approuvé des options d'actions d'incitation pour quatre nouvelles recrues non exécutives. Les attributions couvrent 138,000 actions ordinaires dans le cadre du Plan d'Incinération 2024 de la société, conformément à la règle de cotation 5635(c)(4) de Nasdaq.
Les options d'actions ont été accordées à un prix d'exercice de $21,36, correspondant au prix de clôture des actions ordinaires de NAMS au 3 février 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % qui s'acquièrent après un an et les actions restantes s'acquérant en 36 versements mensuels égaux, subordonnés à un emploi continu.
NewAmsterdam Pharma (Nasdaq: NAMS) gab bekannt, dass das Vergütungskomitee Anreiz-Aktienoptionen für vier neue nicht-executive Mitarbeiter genehmigt hat. Die Zuwendungen betreffen 138.000 Stammaktien im Rahmen des Unternehmens 2024 Anreizplans und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
Die Aktienoptionen wurden zu einem Ausübungspreis von $21,36 gewährt, was dem Schlusskurs der NAMS-Stammaktien am 3. Februar 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % nach einem Jahr fällig werden und die verbleibenden Aktien in 36 gleichen monatlichen Raten fällig werden, abhängig von der fortgesetzten Beschäftigung.
- Successful recruitment of four new non-executive employees indicating company growth
- Implementation of employee retention strategy through stock options
- Potential future dilution of shareholder value through 138,000 new share options
NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 138,000 of NewAmsterdam’s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
How many share options did NewAmsterdam Pharma (NAMS) grant in February 2025?
What is the exercise price for NAMS's February 2025 inducement share options?
What is the vesting schedule for NAMS's 2024 Inducement Plan share options?
How many new employees received NAMS share options under the February 2025 grant?
